HLB Panagene (A046210) Stock Overview
Manufactures and sells genetic diagnostic products in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
A046210 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
HLB Panagene Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,125.00 |
| 52 Week High | ₩2,940.00 |
| 52 Week Low | ₩1,535.00 |
| Beta | 0.031 |
| 1 Month Change | -9.19% |
| 3 Month Change | 26.87% |
| 1 Year Change | 8.47% |
| 3 Year Change | -45.09% |
| 5 Year Change | -62.26% |
| Change since IPO | -78.69% |
Recent News & Updates
Shareholder Returns
| A046210 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -2.7% | 1.7% | 4.1% |
| 1Y | 8.5% | 41.5% | 151.2% |
Return vs Industry: A046210 underperformed the KR Biotechs industry which returned 41.5% over the past year.
Return vs Market: A046210 underperformed the KR Market which returned 151.2% over the past year.
Price Volatility
| A046210 volatility | |
|---|---|
| A046210 Average Weekly Movement | 12.2% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 9.2% |
| 10% most volatile stocks in KR Market | 16.2% |
| 10% least volatile stocks in KR Market | 4.7% |
Stable Share Price: A046210 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A046210's weekly volatility (12%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | 81 | Sung-Ki Kim | www.hlbpanagene.com |
HLB Panagene Co., Ltd. manufactures and sells genetic diagnostic products in South Korea and internationally. It offers PANAMutyper, which detects small amount of mutation with high sensitivity and genotypes multiple mutations for oncology liquid biopsy; PNAClamp, a PNA-based PCR clamping that detects and amplifies only the mutated target DNA sequence for oncology tissue biopsy; PANA RealTyper, a PNA probe-based fluorescence melting curve analysis tool that detects mutation and distinguishes multiple SNPs adjacent for infectious diseases; PANA qPCR, a tool used for multiplexing, allelic discrimination experiments, and quantitative analysis; and PNA, an artificially created DNA analogue. The company was formerly known as Panagene Inc. and changed its name to HLB Panagene Co., Ltd.
HLB Panagene Co., Ltd. Fundamentals Summary
| A046210 fundamental statistics | |
|---|---|
| Market cap | ₩96.63b |
| Earnings (TTM) | -₩3.13b |
| Revenue (TTM) | ₩15.05b |
Is A046210 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A046210 income statement (TTM) | |
|---|---|
| Revenue | ₩15.05b |
| Cost of Revenue | ₩6.24b |
| Gross Profit | ₩8.81b |
| Other Expenses | ₩11.94b |
| Earnings | -₩3.13b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -68.74 |
| Gross Margin | 58.54% |
| Net Profit Margin | -20.77% |
| Debt/Equity Ratio | 21.4% |
How did A046210 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/30 00:57 |
| End of Day Share Price | 2026/04/30 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
HLB Panagene Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.